主动和被动β淀粉样蛋白免疫疗法：临床前和临床研究及未来方向：第二部分 - Suppr

Suppr

超能文献

Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.

作者信息

Cribbs David H, Agadjanyan Michael G

出版信息

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):82-7. doi: 10.2174/187152709787847270.

DOI:10.2174/187152709787847270

PMID:19355929

Abstract

摘要

相似文献

Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):82-7. doi: 10.2174/187152709787847270.

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

Nat Rev Neurosci. 2002 Oct;3(10):824-8. doi: 10.1038/nrn938.

AD vaccines: conclusions and future directions.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):160-6. doi: 10.2174/187152709787847289.

Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):144-59. doi: 10.2174/187152709787847324.

Alternative Abeta immunotherapy approaches for Alzheimer's disease.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. doi: 10.2174/187152709787847306.

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.

Curr Pharm Des. 2011;17(5):508-20. doi: 10.2174/138161211795164112.

Amyloid-beta immunotherapy for Alzheimer's disease.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017.

Amyloid-beta immunisation for Alzheimer's disease.

Lancet Neurol. 2008 Sep;7(9):805-11. doi: 10.1016/S1474-4422(08)70170-4. Epub 2008 Jul 28.

Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. doi: 10.2174/187152709787847298.

Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):98-113. doi: 10.2174/187152709787847333.

引用本文的文献

Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease.

Acta Neuropathol Commun. 2013 Aug 9;1:48. doi: 10.1186/2051-5960-1-48.

The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.

J Transl Med. 2011 Aug 1;9:127. doi: 10.1186/1479-5876-9-127.

DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Gene Ther. 2010 Feb;17(2):261-71. doi: 10.1038/gt.2009.140. Epub 2009 Oct 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.

作者信息

Cribbs David H, Agadjanyan Michael G

出版信息

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):82-7. doi: 10.2174/187152709787847270.

DOI:10.2174/187152709787847270

PMID:19355929

Abstract

摘要

相似文献

Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):82-7. doi: 10.2174/187152709787847270.

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

Nat Rev Neurosci. 2002 Oct;3(10):824-8. doi: 10.1038/nrn938.

AD vaccines: conclusions and future directions.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):160-6. doi: 10.2174/187152709787847289.

Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):144-59. doi: 10.2174/187152709787847324.

Alternative Abeta immunotherapy approaches for Alzheimer's disease.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. doi: 10.2174/187152709787847306.

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.

Curr Pharm Des. 2011;17(5):508-20. doi: 10.2174/138161211795164112.

Amyloid-beta immunotherapy for Alzheimer's disease.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017.

Amyloid-beta immunisation for Alzheimer's disease.

Lancet Neurol. 2008 Sep;7(9):805-11. doi: 10.1016/S1474-4422(08)70170-4. Epub 2008 Jul 28.

Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. doi: 10.2174/187152709787847298.

Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):98-113. doi: 10.2174/187152709787847333.

引用本文的文献

Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease.

Acta Neuropathol Commun. 2013 Aug 9;1:48. doi: 10.1186/2051-5960-1-48.

The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.

J Transl Med. 2011 Aug 1;9:127. doi: 10.1186/1479-5876-9-127.

DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Gene Ther. 2010 Feb;17(2):261-71. doi: 10.1038/gt.2009.140. Epub 2009 Oct 29.